Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritis

Stephanie F Ling^{1

2}, Chuan Fu Yap¹, Nisha Nair^{1

2}, Suzanne M M Verstappen^{2

3}, Ann W Morgan^{4

5}, John D Isaacs^{6

7}, Anthony G Wilson⁸, Kimme L Hyrich^{2

3}, Anne Barton^{1

2}, Darren Plant^{1

2}

Affiliations

¹ Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
² NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
⁴ School of Medicine, University of Leeds, Leeds, UK.
⁵ NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁶ Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
⁷ Musculoskeletal Unit, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
⁸ School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.

Stephanie F Ling et al. Rheumatology (Oxford). 2025.

. 2025 Jul 1;64(7):4417-4419.

doi: 10.1093/rheumatology/keaf235.

¹ Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
² NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
⁴ School of Medicine, University of Leeds, Leeds, UK.
⁵ NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁶ Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
⁷ Musculoskeletal Unit, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
⁸ School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.

No abstract available

Figures

1. Ling SF, Plant D. Multiomics studies in rheumatoid arthritis: the search for the holy grail of predicting treatment response. touchREVIEWS RMD 2024;3:10–2.
1. Otvos JD, Shalaurova I, Wolak-Dinsmore J et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem 2015;61:714–23. - PubMed
1. Bartlett DB, Connelly MA, AbouAssi H et al. A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Res Ther 2016;18:86. - PMC - PubMed
1. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P et al. GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: potential Use as a Biomarker of Subclinical Cardiovascular Disease. J Clin Med 2020;9:2472. - PMC - PubMed
1. Sergeant JC, Hyrich KL, Anderson J et al. ; RAMS Co-Investigators. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther 2018;20:147. - PMC - PubMed